

1 **Predicting the causal relationship between polyunsaturated fatty**
2 **acids and cerebral aneurysm risk from a**
3 **Mendelian randomization study**

4 **Authors**

5 Weijie Yu^{1†}, Liwei Zhou^{3†}, Chongfei Li^{2,3†}, Zhenwei Lu^{2,3}, Xiaoyu Chen⁴, Hao Yu⁴, Xiaoyan Chen⁵,

6 Qionghui Huang^{2,6}, Zhangyu Li³, Deyong Xiao³, Yunyun Mei^{7*}, Zhanxiang Wang^{3*}

7 **Author Affiliations**

8 1 Department of Neurosurgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou,
9 China.

10 2 The School of Clinical Medicine, Fujian Medical University, Fuzhou 350122, China.

11 3 Department of Neurosurgery, Department of Neurosurgery Quality Control Center, The First
12 Affiliated Hospital of Xiamen University, Xiamen Key Laboratory of Brain Center, Xiamen 361003,
13 China.

14 4 School of Medicine, Xiamen University, Xiamen 361005, China.

15 5 Internal medicine, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China.

16 6 Department of Anesthesiology, The First Affiliated Hospital of Xiamen University, Xiamen Key
17 Laboratory of Brain Center, Xiamen 361003, China.

18 7 Department of Neurosurgery, Fudan University Shanghai Cancer Center Xiamen Hospital, Xiamen
19 361026, China.

20

21 **†Co-first author**

22 Weijie Yu, Liwei Zhou and Chongfei Li contributed equally as the first authors.

23 *** Corresponding Author**

24 Yunyun Mei, MS. Department of Neurosurgery, Department of Neurosurgery, Fudan University

25 Shanghai Cancer Center Xiamen Hospital, 99 Dongfu West Road, Haicang District, Xiamen City,

26 Fujian, 361003, P.R. China (Email: 15985997536@163.com).

27 Zhanxiang Wang, MD. Department of Neurosurgery, The First Affiliated Hospital of Xiamen

28 University, Xiamen Key Laboratory of Brain Center, 55 Zhenhai Road, Xiamen Siming District,

29 Xiamen City, Fujian, 361003, P.R. China (Email: zhanxiangW_sjwk@163.com).

30

31 **Abstract**

32 **Introduction:** No conclusive evidence for a link between polyunsaturated fatty acids (PUFA) and
33 cerebral aneurysm has been found in observational research. The aim of our study was to determine the
34 causal impact of PUFA on cerebral aneurysm.

35 **Methods:** Two sample Mendelian randomization (MR) was performed using genetic instruments
36 derived from a recent genome wide association study (GWAS) of fatty acids from UK Biobank and
37 outcome data obtained from the large-scale cerebral aneurysm GWASs in European ancestry which
38 include IA, aneurysmal subarachnoid hemorrhage (aSAH) and unruptured intracranial aneurysm (uIA).
39 Sensitivity analyses were implemented with MVMR, MR-Egger intercept test, MR-PRESSO,
40 leave-one-out analysis and so on. Bayesian colocalization (COLOC) methods was conducted to focus
41 on the association between the fatty acid gene expression and cerebral aneurysm.

42 **Results:** Genetically predicted assessed omega-3 fatty acids decreased the risk for IA (OR = 0.80, 95%
43 CI: 0.69 - 0.91, $P = 1.01 \times 10^{-3}$) and aSAH (OR = 0.71, 95% CI: 0.61 - 0.84, $P = 3.73 \times 10^{-5}$). Furthermore,
44 the Docosahexaenoic acid decreased the risk for IA (OR = 0.75, 95% CI: 0.63 - 0.87, $P = 3.12 \times 10^{-4}$)
45 and aSAH (OR = 0.67, 95% CI: 0.55 - 0.8, $P = 2.32 \times 10^{-5}$). The same results were discovered from ratio
46 of omega-3 fatty acids to total fatty acids. While the ratio of omega-6 fatty acids to omega-3 fatty acids
47 increased the risk of IA (OR = 1.27, 95% CI: 1.12 - 1.44, $P = 1.53 \times 10^{-4}$) and aSAH (OR = 1.35, 95%
48 CI: 1.17 - 1.56, $P = 5.78 \times 10^{-5}$). The result of the COLOC suggested that the above four kinds of fatty
49 acids and IA, aSAH likely share causal variants in gene fatty acid desaturase 2, separately.

50 **Conclusion:** This study utilized integrative analysis of MR and colocalization to discover causal
51 relationships between genetic variants, PUFA and cerebral aneurysm.

52 **Funding:** This study was funded by the Natural Science Foundation of China (82072777), the Natural
53 Science Foundation of Xiamen (3502Z20227097), Fujian Provincial Health Commission, Provincial
54 Health and Health Young and Middle-aged Backbone Talent Training Project (2022GGB010).

55

56 **Keywords:** polyunsaturated fatty acids, intracranial aneurysm, subarachnoid hemorrhage, Mendelian
57 randomization.

58

59

60 **Introduction**

61 Intracranial aneurysm (IA) is confined, pathological dilatations of the walls of intracranial arteries,
62 which currently considered a chronic inflammatory disease that affects the intracranial arteries (Aoki et
63 al., 2017) with a prevalence of approximately 3% in the general population (Vlak et al., 2011). About
64 85% of spontaneous subarachnoid hemorrhage (SAH) is due to ruptured IA (Macdonald et al., 2017).
65 Unruptured IAs (uIAs) are frequently asymptomatic, but IA rupture can result in aneurysmal
66 subarachnoid hemorrhage (aSAH), which has a poor prognosis (30% of death, 30% of independence
67 and 30% of dependence), with patients often suffering from a disability or even death (Chen et al.,
68 2020; (Nieuwkamp et al., 2009). In light of the elevated rates of mortality and morbidity brought on
69 by IA, it is crucial to explore the pathogenesis of intracranial aneurysm.

70 Polyunsaturated fatty acids (PUFA) are fatty acids that contain multiple double bonds in their
71 molecular structure. According to the position and number of double bonds, polyunsaturated fatty acids
72 can be further divided into two categories, omega-3 and omega-6. The long-chain omega-3
73 polyunsaturated fatty acid (omega-3) and docosahexaenoic acid (DHA) have been suggested to have
74 cardioprotective (Burr et al., 1989; (Wang et al., 2006), anti-inflammatory (Massaro et al., 2006),
75 immunoregulatory (Yang et al., 2013), antioxidant (Carrepeiro et al., 2011; (Bouzidi et al., 2010) and
76 anti-tumor activities (Calviello et al., 2006). A recent study reported a significant decrease in red blood
77 cell distribution width, pulse wave analysis and heart rate in patients with abdominal aortic aneurysm
78 who were supplemented with 1.8 g of long-chain omega-3 polyunsaturated fatty acids for 12 weeks,
79 suggesting an improving in intravascular inflammation and vascular stiffness (Meital et al., 2019;
80 (Meital et al., 2020). Omega-3 and DHA down-regulate multiple aspects of the inflammatory process,
81 such as oxidative stress and inflammation in macrophages (Meital et al., 2019). According to a recent
82 retrospective study, high levels of free fatty acids on admission can provide some reference predictions
83 for the poor prognosis of patients with aSAH at 3 months (Wang et al., 2021). Other studies
84 demonstrated that arachidonic acid (AA) and AA-containing phospholipids were not detected in
85 unruptured IA walls, whereas AA and AA-containing phospholipids were detected in significantly
86 higher amounts in ruptured IA walls than in unruptured IA walls (Takeda et al., 2021).

87 Mendelian randomization (MR) is the use of genetic variation in non-experimental data to
88 estimate the causal link between exposure and outcome, and it can reduce the impact of behavioral,
89 social, psychological, and other factors (Davey Smith et al., 2014). And in recent years, many MR
90 studies have emerged to provide clinical evidence (Hu et al., 2023; (Yuan et al., 2019). To investigate
91 the etiology of cerebral aneurysms, it is essential to further clarification of the causal relationship
92 between PUFAs and cerebral aneurysms through Mendelian randomization.

93 **Methods**

94 **Study design**

95 In this study, we performed a two-sample Mendelian randomization analysis to examine the
96 causal effects of PUFA and cerebral aneurysms using genome wide association study (GWAS)
97 summary statistics. This instrumental-variable analysis mimics RCT with respect to the random
98 allocation of single nucleotide polymorphisms (SNPs) in offspring (independent of confounding factors
99 such as sex and age). In addition, this MR design has to fulfill three assumptions: (i) genetic

100 instruments predict the exposure of interest ($P < 5 \times 10^{-8}$); (ii) genetic instruments are independent of
101 potential confounders; (iii) genetic instruments affects the outcome only via the risk factors (Boef et al.,
102 2015). The MR analysis used summary GWAS data publicly available from GWASs and no individual
103 level data used. Due to the fact that each of the original GWASs had obtained ethical approval and
104 participant consent, they were not required.

105 **Data source and selection of genetic instruments**

106 SNPs associated with 5 PUFAs were obtained from the open GWAS website, containing omega-3
107 fatty acids, omega-6 fatty acids, DHA, the ratio of omega-3 fatty acids to total fatty acids and the ratio
108 of omega-6 fatty acids to omega-3 fatty acids. According to the GWAS ID, we named the ratio of
109 omega-3 fatty acids to total fatty acids and ratio of omega-6 fatty acids to omega-3 fatty acids
110 abbreviated as omega-3-pct and omega-6 by omega-3, respectively. They are derived from a
111 large-scale UK Biobank GWAS of fatty acids with 114,999 individuals of European ancestry (Borges
112 et al., 2022). Circulating omega-3 (i.e., DHA and total omega-3) and omega-6 (i.e., linoleic acid and
113 total omega-6) fatty acid concentration were measured using a targeted high-throughput nuclear
114 magnetic resonance metabolomics platform (Julkunen et al., 2021). The mean concentration of total
115 omega-3 fatty acids, DHA and omega-6 fatty acids was 0.53 (SD 0.22) mmol/L, 0.23 (SD 0.08)
116 mmol/L and 4.45 (SD 0.68) mmol/L. (Supplementary Table 1)

117 For the outcome, the genetic effect of the corresponding SNP on IA and aSAH were obtained
118 from the most recent GWAS with a total of 65796 Europeans (6252 IA cases and 59544 controls) and
119 63740 Europeans (4196 aSAH cases and 59544 controls) after excluding UK Biobank (Bakker et al.,
120 2020). And Summary statistics for uIA phenotypes were extracted from the FinnGen database
121 (https://r8.finnngen.fi/pheno/I9_ANEURYSM) with a total of 314556 Europeans (1788 uIA cases and
122 312768 controls). (Supplementary Table 1)

123 According to three essential model assumptions of MR. First, SNPs were associated with the
124 appropriate exposure at the genome-wide significance threshold $P < 5 \times 10^{-8}$. Second, to quantify the
125 strength of the genetic instruments, SNPs with an F statistic less than 10 were excluded. Third, we
126 clustered SNPs in linkage disequilibrium (LD, $R^2 \geq 0.001$ and within 10 mb). Fourth, remove SNPs that
127 are obscure, palindromic, and linked to recognized confounding variables (body mass index
128 (McDowell et al., 2018), blood pressure (Sun et al., 2022), type 2 diabetes (Tian et al., 2022),
129 high-density lipoprotein (Huang et al., 2018)). Fifth, If an instrumental SNP for the exposure was not
130 available from the outcome data set, we replaced it with a suitable proxy SNP ($r^2 > 0.8$ in the European
131 1000 Genomes Project reference panel using LDlink <https://ldlink.nci.nih.gov/>) or removed it in the
132 absence of such a proxy. SNPS located in the MHC region were removed. Finally, removing SNPs
133 with potential pleiotropy and outlier through mendelian randomization pleiotropy residual sum and
134 outlier (MR-PRESSO). Then, the heterogeneity between-SNP were tested using inverse variance
135 weighting (IVW) and the MR-Egger method based on the SNPs that were retained after pleiotropy
136 correction. (Figure 1.) It can be observed that the final SNPs for each group is not identical. Details
137 of the SNPs used as instrumental variables were displayed in Supplementary Tables 2 - 4.

138 **Mendelian randomization analyses**

139 Eleven MR analytical approaches were used in this study to investigate the causal impacts of PUFA on
140 the cerebral aneurysm. As the main analysis, we used standard IVW estimates, which are characterized
141 by an analysis that does not take into account the presence of an intercept term and uses the inverse of
142 the outcome variance (quadratic of the standard error) as a weight to provide a comprehensive estimate
143 of the impact of the PUFA on the cerebral aneurysm. Furthermore, additional MR analyses, such as
144 MR-Egger regression, weighted median, simple mode, weighted mode methods and so on were
145 implemented as complements to the IVW, because these methods could provide more robust estimates
146 over a wider range of scenarios. The MR-Egger method can provide causal estimates that are
147 unaffected by breaches of standard IV assumptions and can detect whether standard IV assumptions are
148 violated (Bowden et al., 2015). The weighted median method provides consistent estimates of effect,
149 when at least half of the weighted variance provided by horizontal pleiotropy is valid (Bowden et al.,
150 2016). We also performed reverse MR studies, where the cerebral aneurysms were treated as the
151 exposure and PUFA was treated as the result, in order to thoroughly investigate the potential existence
152 of reverse causation.

153 **Sensitivity analysis**

154 For comparison with univariate MR results, to remove bias from closely related lipid traits, we
155 performed multivariable Mendelian randomization- IVW (MVMR- IVW), adjusting for HDL
156 cholesterol, LDL cholesterol, total cholesterol and triglycerides (Borges et al., 2022). To assess the
157 robustness of the above results, a series of sensitivity analyses, including IVW, MR-Egger, MR-Egger
158 intercept test, MR-PRESSO global test and “leave-one-out” were conducted. Furthermore, FADS2 and
159 its SNPs within 500 kb of the FADS2 locus were removed based on the results of leave one out for the
160 purpose of performing sensitivity analyses.

161 **Bayesian colocalization (COLOC)**

162 Bayesian colocalization (COLOC) analysis assesses whether single-nucleotide variants linked to gene
163 expression and phenotype at the same locus are shared causal variants, and thus, gene expression and
164 phenotype are “colocalized.” This approach assumes that: (1) in each test region, there exists at most
165 one causal SNP for either trait; (2) the probability that a SNP is causal is independent of the probability
166 that any other SNP in the genome is causal; (3) all causal SNPs are genotyped or imputed and included
167 in analysis. According to these assumptions, there are five mutually exclusive hypotheses for each test
168 region: (1) there is no causal SNP for either trait (H0); (2) there is one causal SNP for trait 1 only (H1);
169 (3) there is one causal SNP for trait 2 only (H2); (4) there are two distinct causal SNPs, one for each
170 trait (H3); and (5) there is a causal SNP common to both traits (H4). A large PP for H4 (PP.H4 above
171 0.75) strongly supports shared causal variants affecting both gene expression and phenotype (Kurki et
172 al., 2023). **Statistical Analysis**

173 For the MR analysis, IVs with F values over 10 were considered strong instruments that could
174 alleviate bias from weak instruments (Pierce et al., 2011). The formula used to calculate F values is as
175 follows: $F = [(N-K-1) R^2] / [k(1-R^2)]$, where R^2 represents the proportion of variance explained by the
176 genetic variants, N represents the sample size, and k represents the number of included SNPs. $R^2 =$
177 $\sum_1^k 2\beta^2(1 - EAF)EAF$, where EAF is the effect allele frequency and β is the estimated effect on LTL

178 (Park et al., 2010). Given the limited number of cases in the GWAS, we calculated the statistical power
179 for MR analysis using the mRnd website (<https://shiny.cnsgenomics.com/mRnd/>). To account for
180 multiple testing in our primary analyses, a Bonferroni-corrected threshold of $P < 0.0033$ ($\alpha=0.05/15$ [5
181 exposures and 3 outcomes]) was applied. All statistical analyses performed in this investigation were
182 carried out using the “TwoSampleMR”, “phenoscanner”, “RadialMR”, “MendelianRandomization”
183 and “MRPRESSO” packages in R software (version 4.2.2).

184 **Results**

185 According to the above methodology, we filtered out the corresponding SNPs. (Supplementary
186 Table 2 – 4)

187 In the outcome of IA, IVW analysis indicated that omega-3 fatty acid (OR = 0.80, 95% CI: 0.69 -
188 0.91, $P = 1.01 \times 10^{-3}$), DHA (OR = 0.75, 95% CI: 0.63 - 0.87, $P = 3.12 \times 10^{-4}$) and omega-3-pct (OR = 0.8,
189 95% CI: 0.71 - 0.90, $P = 2.34 \times 10^{-4}$) decreased the risk for IA. And omega-6 by omega-3 increased the
190 risk for IA (OR = 1.27, 95% CI: 1.12 – 1.44, $P = 1.53 \times 10^{-4}$). The results demonstrated consistency in
191 the outcomes and directionality of the various MR methods employed. (Supplementary Figure 1)
192 Nevertheless, there was no link found between omega-6 fatty acid and IA. (Figure 2) The results of the
193 MVMR demonstrated that omega-3, DHA, and omega-3-pct were also effective in reducing the
194 incidence of IA following appropriate adjustments for HDL cholesterol, LDL cholesterol, total
195 cholesterol and triglycerides. Furthermore, an elevated ratio of omega-6 by omega-3 was associated
196 with an increased risk of developing IA. (Figure 5)

197 In the outcome of aSAH, omega-3 fatty acid (OR = 0.71, 95% CI: 0.61 - 0.84, $P = 3.73 \times 10^{-5}$),
198 DHA (OR = 0.67, 95% CI: 0.55 - 0.80, $P = 2.32 \times 10^{-5}$) and omega-3-pct (OR = 0.76, 95% CI: 0.66 -
199 0.87, $P = 1.16 \times 10^{-4}$) decreased the risk for aSAH. And omega-6 by omega-3 increased the risk for
200 aSAH (OR = 1.35, 95% CI: 1.17 – 1.56, $P = 5.78 \times 10^{-5}$). The results and directionality of other MR
201 methods revealed consistency. (Supplementary Figure 2) However, there was no causal relationship
202 between omega-6 fatty acid and aSAH. (Figure 3.) After adjustment for HDL cholesterol, LDL
203 cholesterol, total cholesterol and triglycerides, the results of the MVMR demonstrated that omega-3,
204 DHA and omega-3-pct were also effective in reducing the incidence of IA. (Figure 6)

205 In the outcome of uIA, there was no causal relationship between all of the above five PUFAs and
206 uIA. (Figure 4.) In the result of reverse MR, MR analysis of all groups failed sterling the filiting test.
207 Adjusted MVMR still shows negative results. (Figure 7)

208 To assess the robustness of the above results, a series of sensitivity analyses, including MR-Egger,
209 IVW, MR-Egger intercept test, “leave-one-out” method and MR-PRESSO global test, were conducted
210 (Supplementary Table 5 and Supplementary Figure 3-5). All P-values of the MR-Egger intercept tests,
211 Q test and MR-PRESSO were > 0.05 , indicating that no horizontal pleiotropy and heterogeneity existed.
212 All steiger tests indicated correct directionality. The leave-one-out plot demonstrates that there is a

213 potentially influential SNP (rs174564) driving the causal link between PUFA and cerebral aneurysm.
214 We conducted further sensitivity analyses after removing rs174564 and its SNPs within 500 kb of the
215 *FADS2* locus. The results demonstrated that the p-values were all greater than 0.0033, indicating that
216 SNP: rs174564 was a significant factor driving the causal association between PUFAs and CA. (Figure
217 8)

218 There is consistent evidence that PUFAs have a beneficial causal effect on cerebral aneurysm. In
219 order to determine an MR estimate is not confounded by LD, we used COLOC to identify shared
220 causal SNP between PUFAs and cerebral aneurysms. In COLOC analysis, we further calculated the
221 posterior probability of each SNP being causal to both of the traits (PPH4). We identified shared causal
222 SNP of omega-3 fatty acid and IA, aSAH in gene fatty acid desaturase 2 (*FADS2*), respectively.
223 Similarly, in DHA, omega-3-pct and omega-6 by omega-3, these three fatty acids and IA, aSAH also
224 obtain the same result. (Table 1 and Supplementary Table 6_1- 6_8)

225

226

227 Discussion

228 PUFA supplementation is controversial for the prevention of cerebral aneurysm disease, while
229 cerebral aneurysm is a heterogeneous disease with various pathogenic mechanisms. Here, we
230 implemented multiple rigorous MR methods to appraise the possible causal association of PUFA with
231 cerebral aneurysm and its different states. We demonstrated that the omega-3 fatty acids, DHA and
232 omega-3-pct causally decreased the risk for IA and aSAH. And omega-6 by omega-3 causally
233 increased the risk of IA and aSAH. In addition to IVW, consistency was seen in the outcomes and
234 directionality of different MR methods. The results of the MVMR and sensitivity analysis provide
235 further evidence of the causal association between PUFAs and IA, aSAH. We identified shared causal
236 SNPs of omega-3 fatty acid, DHA, omega-3-pct, omega-6 by omega-3 and IA in genes *FADS2*,
237 respectively. The same results were acquired from these four PUFAs and aSAH. The results of reverse
238 MR and COLOC jointly increase the validity of our findings.

239 This could be connected to PUFAs, which can decrease the aneurysm's inflammatory process. The
240 pathophysiology of IA involves inflammatory processes (Ge et al., 2022), which may include
241 degeneration of the endothelium and vasa vasorum, as well as fragmentation of the internal elastic
242 lamina (Nakatomi et al., 2000; Meng et al., 2014). As an underlying mechanism, the prostaglandin
243 E2 in macrophages was considered by Aoki et al. as a factor regulating such chronic inflammation
244 involved in the progression and rupture of IAs (Aoki et al., 2017). However, multiple elements of the
245 inflammatory process, including oxidative stress and inflammation in macrophages, can be
246 downregulated by omega-3 and DHA (Meital et al., 2019). In the abdominal aortic aneurysm (AAA),
247 supplementation with the omega-3 PUFA, DHA, suppressed production of 8-isoprostane, the gold
248 standard biomarker of oxidative stress and a specific marker of lipid peroxidation (Kadiiska et al.,
249 2005). The results concord with data from both experimental animal studies (Saraswathi et al., 2007;
250 Zúñiga et al., 2010) and human clinical trials (Mori et al., 2003; Barden et al., 2015) that suggest
251 omega-3 PUFAs decrease 8-isoprostane levels and ease oxidative stress. The findings from a
252 randomized controlled trial suggest that omega-3 PUFAs improve erythrocyte fatty acid profile and
253 ameliorate factors associated with inflammation in AAA patients (Meital et al., 2019). For aSAH, a

254 prospective study demonstrated that administration of omega-3 fatty acids after aneurysmal SAH may
255 reduce the frequency of cerebral vasospasm through the effects of anti-inflammatory and reduce both
256 platelet aggregation and plasma triglycerides, and have neuroprotective effects and may improve
257 clinical outcomes (Nakagawa et al., 2017). At the same time, it may have a preventive effect on the
258 complication of intracranial hemorrhage after aneurysm surgery (Saito et al., 2017). A multi-center
259 study with a sizable sample size is still required to clarify the trend of the effect of omega-3 fatty acids
260 on aSAH, even though the favorable outcomes of these two studies have a certain reference value.
261 Furthermore, Ririko et al. findings that AA and AA-containing phospholipids were not detected in the
262 unruptured IA while they were detected in a significantly larger amount in the ruptured IA and suggest
263 that the stability of the turnover of AA and linoleic acid in human unruptured IA walls is sustained
264 (Takeda et al., 2021). Several earlier studies employing rat model found that the thickened aneurysmal
265 wall and various brain areas after subarachnoid hemorrhage had higher amounts of free fatty acids,
266 including AA (Gewirtz et al., 1999; Ikedo et al., 2018). This is in line with results of our MR
267 analyses between omega-6 fatty acid and aSAH.

268 Besides, in the development of cardiovascular disease, genetically higher plasma α -linolenic and
269 linoleic levels are inversely associated with large-artery stroke and venous thromboembolism, whereas
270 AA level have a favorable correlation with these cardiovascular diseases (Yuan et al., 2019). This may
271 be associated with the $\Delta 5$ -desaturase and $\Delta 6$ -desaturase, which are the primary rate-limiting enzyme
272 for the synthesis of inborn long-chain PUFAs and is encoded by the fatty acid desaturase 1 (*FADS1*)
273 gene and fatty acid desaturase 2 (*FADS2*) gene (Simopoulos, 2010). Even the aortic valve's fatty acid
274 composition might be impacted by *FADS1* (Plunde et al., 2020). In our COLOC analysis, we
275 identified shared causal SNP of omega-3 fatty acid and IA, aSAH in gene fatty acid desaturase 2
276 (*FADS2*), respectively. The same result was also found in DHA, omega-3-pct and omega-6 by omega-3.
277 Furthermore, sensitivity analyses of removing the *FADS2* locus yielded analogous results, thereby
278 corroborating the result that *FADS2* drives the causal relationship. It is obvious that omega-3 fatty
279 acids play a vital role in vascular-related diseases. Conversely, it's incorrect to assume that all forms of
280 omega-6 fatty acids would worsen blood vessel damage. More thorough large-sample study is still
281 required for additional validation.

282 However, several limitations should be taken into account in our study. First, given that the
283 participants in this study were from European population, the results of this study cannot be smoothly
284 extrapolated to other ethnic groups with diverse lifestyles and cultural backgrounds. Hence, further
285 multi-ancestry studies are needed to evaluate whether our findings can be generalized to individuals of
286 other ancestries. Second, since MR analyses extrapolated causal hypotheses by exploiting the random
287 allocation of genetic variants, it was difficult to completely distinguish between mediation and
288 pleiotropy using MR approaches. The generous variants in our genome probably affect one or more
289 phenotypes, even though we made an effort to remove the impacts of pleiotropic and heterogeneous
290 factors and confounders, some effects may still be there. Third, not all SNPs were examined, as some
291 were removed because of LD (and no proxy SNPs were found), which may have impacted the results.
292 Fourth PUFAs were measured from nonfasting peripheral plasma specimens, not aneurysm cavity
293 blood and aneurysm wall tissue Fifth, there is currently a lack of GWAS datasets of cerebral aneurysms
294 from different cerebrovascular sites, and exploring the relationship between genetically predicted
295 PUFAs and the occurrence of specific types of cerebral aneurysms remains a challenge in current MR
296 analyses.

297 **Conclusion**

298 In view of the extremely poor prognosis of cerebral aneurysms and the high mortality rate of
299 secondary rupture, our research focuses on the causal relationship between PUFAs and cerebral
300 aneurysms to improve our understanding of the pathogenic mechanism of various PUFAs in cerebral
301 aneurysms. And provide new insights into the diagnosis and treatment of brain aneurysms in the future.

302 **Acknowledgements**

303 The authors want to acknowledge all of the participants and investigators for contributing and sharing
304 summary-level data on GWAS.

305 **Consent for Publication**

306 All participants provided informed consent before enrollment in our study.

307 **Disclosures**

308 The authors declare that they have no competing interests.

309 **Author contributions**

310 Study design: Weijie Yu, Yunyun Mei, Liwei Zhou and Zhanxiang Wang. Acquisition of datasets:

311 Weijie Yu, Yunyun Mei, Chongfei Li, Xiaoyan Chen, Zhenwei Lu, Qionghui Huang and Zhangyu Li.

312 Data analysis: Weijie Yu, Yunyun Mei and Chongfei Li. Manuscript drafting: Weijie Yu and Yunyun

313 Mei. Manuscript revision: Liwei Zhou and Zhanxiang Wang. Final approval of manuscript: all authors.

314 **Ethical Approval**

315 Due to the fact that each of the original GWASs had obtained ethical approval and participant consent,

316 they were not required.

317 **Data availability**

318 The original contributions presented in the study are included in the article/supplementary material.

319 Further inquiries can be directed to the corresponding author.

320

321 **References**

322 Aoki T, Fransen J, Fukuda M, Bando K, Shioi G, Tsuji K, Ollikainen E, Nozaki K, Laakkonen J,
323 Narumiya S. 2017. Prostaglandin E2-EP2-NF- κ B signaling in macrophages as a potential therapeutic
324 target for intracranial aneurysms. *Science signaling*. 10465. DOI: 10.1126/scisignal.aah6037

325 Vlak MH, Algra A, Brandenburg R, Rinkel GJ. 2011. Prevalence of unruptured intracranial aneurysms,
326 with emphasis on sex, age, comorbidity, country, and time period: a systematic review and
327 meta-analysis. *The Lancet Neurology*. 107:626-636. DOI: 10.1016/s1474-4422(11)70109-0

328 Macdonald RL, Schweizer TA. 2017. Spontaneous subarachnoid haemorrhage. *The Lancet*.

329 Chen Y, Wright N, Guo Y, Turnbull I, Kartsonaki C, Yang L, Bian Z, Pei P, Pan D, Zhang Y, Qin H,

- 330 Wang Y, Lv J, Liu M, Hao Z, Wang Y, Yu C, Peto R, Collins R, Li L, Clarke R, Chen Z. 2020.
331 Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of
332 0.5 million Chinese adults. *The Lancet Global health*. 84:e580-e590. DOI:
333 10.1016/s2214-109x(20)30069-3
- 334 Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. 2009. Changes in case fatality of
335 aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis.
336 *The Lancet Neurology*. 87:635-642. DOI: 10.1016/s1474-4422(09)70126-7
- 337 Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM.
338 1989. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and
339 reinfarction trial (DART). *Lancet (London, England)*. 28666:757-761. DOI:
340 10.1016/s0140-6736(89)90828-3
- 341 Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J. 2006. n-3
342 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular
343 disease outcomes in primary- and secondary-prevention studies: a systematic review. *The American*
344 *journal of clinical nutrition*. 841:5-17. DOI: 10.1093/ajcn/84.1.5
- 345 Massaro M, Habib A, Lubrano L, Del Turco S, Lazzarini G, Bourcier T, Weksler BB, De Caterina R.
346 2006. The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction
347 through both NADP(H) oxidase and PKC epsilon inhibition. *Proceedings of the National Academy of*
348 *Sciences of the United States of America*. 10341:15184-15189. DOI: 10.1073/pnas.0510086103
- 349 Yang YC, Lii CK, Wei YL, Li CC, Lu CY, Liu KL, Chen HW. 2013. Docosahexaenoic acid inhibition
350 of inflammation is partially via cross-talk between Nrf2/heme oxygenase 1 and IKK/NF-κB pathways.
351 *The Journal of nutritional biochemistry*. 241:204-212. DOI: 10.1016/j.jnutbio.2012.05.003
- 352 Carrepeiro MM, Rogero MM, Bertolami MC, Botelho PB, Castro N, Castro IA. 2011. Effect of n-3
353 fatty acids and statins on oxidative stress in statin-treated hypercholesterolemic and
354 normocholesterolemic women. *Atherosclerosis*. 2171:171-178. DOI:
355 10.1016/j.atherosclerosis.2010.12.013
- 356 Bouzidi N, Mekki K, Boukaddoum A, Dida N, Kaddous A, Bouchenak M. 2010. Effects of omega-3
357 polyunsaturated fatty-acid supplementation on redox status in chronic renal failure patients with
358 dyslipidemia. *Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the*
359 *National Kidney Foundation*. 205:321-328. DOI: 10.1053/j.jrn.2010.01.002
- 360 Calviello G, Serini S, Palozza P. 2006. n-3 polyunsaturated fatty acids as signal transduction
361 modulators and therapeutical agents in cancer. *Current Signal Transduction Therapy*. 13:255-271.
- 362 Meital LT, Windsor MT, Ramirez Jewell RML, Young P, Schulze K, Magee R, O'Donnell J, Jha P,
363 Perissiou M, Golledge J, Bailey TG, Brooks P, Askew CD, Russell FD. 2019. n-3 PUFAs improve
364 erythrocyte fatty acid profile in patients with small AAA: a randomized controlled trial. *Journal of lipid*
365 *research*. 606:1154-1163. DOI: 10.1194/jlr.P093013
- 366 Meital LT, Schulze K, Magee R, O'Donnell J, Jha P, Meital CY, Donkin R, Bailey TG, Askew CD,
367 Russell FD. 2020. Long Chain Omega-3 Polyunsaturated Fatty Acids Improve Vascular Stiffness in
368 Abdominal Aortic Aneurysm: A Randomized Controlled Trial. *Nutrients*. 131. DOI:
369 10.3390/nu13010138
- 370 Meital LT, Windsor MT, Perissiou M, Schulze K, Magee R, Kuballa A, Golledge J, Bailey TG, Askew
371 CD, Russell FD. 2019. Omega-3 fatty acids decrease oxidative stress and inflammation in macrophages
372 from patients with small abdominal aortic aneurysm. *Scientific reports*. 91:12978. DOI:
373 10.1038/s41598-019-49362-z

- 374 Wang Y, Xie Y, Wang H, Zhang J, Li C, Chen F, Ren C, Xu Z, Liu M, Li L, Li T, Wang W. 2021.
375 Development and Clinical Translation of a Perioperative Nomogram Incorporating Free Fatty Acids to
376 Predict Poor Outcome of Aneurysmal Subarachnoid Hemorrhage Following Endovascular Treatment.
377 *Frontiers in neurology*. 12:629997. DOI: 10.3389/fneur.2021.629997
- 378 Takeda R, Islam A, Sato T, Kurita H, Kahyo T, Urano T, Setou M. 2021. The stability of the metabolic
379 turnover of arachidonic acid in human unruptured intracranial aneurysmal walls is sustained. *Clinical*
380 *neurology and neurosurgery*. 208:106881. DOI: 10.1016/j.clineuro.2021.106881
- 381 Davey Smith G, Hemani G. 2014. Mendelian randomization: genetic anchors for causal inference in
382 epidemiological studies. *Human molecular genetics*. 23R1:R89-98. DOI: 10.1093/hmg/ddu328
- 383 Hu C, Zhou Y, Wu X, Jia X, Zhu Y, Zheng R, Wang S, Lin L, Qi H, Lin H, Li M, Wang T, Zhao Z, Xu
384 M, Xu Y, Chen Y, Ning G, Borges MC, Wang W, Zheng J, Bi Y, Lu J. 2023. Evaluating the distinct
385 pleiotropic effects of omega-3 fatty acids on type 2 diabetes mellitus: a mendelian randomization study.
386 *Journal of translational medicine*. 211:370. DOI: 10.1186/s12967-023-04202-7
- 387 Yuan S, Bäck M, Bruzelius M, Mason AM, Burgess S, Larsson S. 2019. Plasma Phospholipid Fatty
388 Acids, FADS1 and Risk of 15 Cardiovascular Diseases: A Mendelian Randomisation Study. *Nutrients*.
389 1112. DOI: 10.3390/nu11123001
- 390 Boef AG, Dekkers OM, le Cessie S. 2015. Mendelian randomization studies: a review of the
391 approaches used and the quality of reporting. *International journal of epidemiology*. 442:496-511. DOI:
392 10.1093/ije/dyv071
- 393 Borges MC, Haycock PC, Zheng J, Hemani G, Holmes MV, Davey Smith G, Hingorani AD, Lawlor
394 DA. 2022. Role of circulating polyunsaturated fatty acids on cardiovascular diseases risk: analysis
395 using Mendelian randomization and fatty acid genetic association data from over 114,000 UK Biobank
396 participants. *BMC medicine*. 201:210. DOI: 10.1186/s12916-022-02399-w
- 397 Julkunen H, Cichońska A, Slagboom PE, Würtz P. 2021. Metabolic biomarker profiling for
398 identification of susceptibility to severe pneumonia and COVID-19 in the general population. *eLife*. 10.
399 DOI: 10.7554/eLife.63033
- 400 Bakker MK, van der Spek RAA, van Rheenen W, Morel S, Bourcier R, Hostettler IC, Alg VS, van Eijk
401 KR, Koido M, Akiyama M, Terao C, Matsuda K, Walters RG, Lin K, Li L, Millwood IY, Chen Z,
402 Rouleau GA, Zhou S, Rannikmäe K, Sudlow CLM, Houlden H, van den Berg LH, Dina C, Naggara O,
403 Gentric JC, Shotar E, Eugène F, Desal H, Winsvold BS, Børte S, Johnsen MB, Brumpton BM, Sandvei
404 MS, Willer CJ, Hveem K, Zwart JA, Verschuren WMM, Friedrich CM, Hirsch S, Schilling S,
405 Dauvillier J, Martin O, Jones GT, Bown MJ, Ko NU, Kim H, Coleman JRI, Breen G, Zaroff JG, Klijn
406 CJM, Malik R, Dichgans M, Sargurupremraj M, Tatlisumak T, Amouyel P, Debette S, Rinkel GJE,
407 Worrall BB, Pera J, Slowik A, Gaál-Paavola EI, Niemelä M, Jääskeläinen JE, von Und Zu Fraunberg M,
408 Lindgren A, Broderick JP, Werring DJ, Woo D, Redon R, Bijlenga P, Kamatani Y, Veldink JH, Ruigrok
409 YM. 2020. Genome-wide association study of intracranial aneurysms identifies 17 risk loci and genetic
410 overlap with clinical risk factors. *Nature genetics*. 5212:1303-1313. DOI:
411 10.1038/s41588-020-00725-7
- 412 McDowell MM, Zhao Y, Kellner CP, Barton SM, Sussman E, Claassen J, Ducruet AF, Connolly ES.
413 2018. Demographic and clinical predictors of multiple intracranial aneurysms in patients with
414 subarachnoid hemorrhage. *Journal of neurosurgery*. 1284:961-968. DOI: 10.3171/2017.1.Jns162785
- 415 Sun X, Liu B, Chen Y, Lv L, Ye D, Mao Y. 2022. Modifiable risk factors for intracranial aneurysms:
416 Evidence from genetic studies. *International journal of stroke : official journal of the International*
417 *Stroke Society*. 1710:1107-1113. DOI: 10.1177/17474930211065640

- 418 Tian D, Zhang L, Zhuang Z, Huang T, Fan D. 2022. A two-sample Mendelian randomization analysis
419 of modifiable risk factors and intracranial aneurysms. *Scientific reports*. 121:7659. DOI:
420 10.1038/s41598-022-11720-9
- 421 Huang Q, Shang-Guan HC, Wu SY, Yao PS, Sun Y, Zeng YL, Zheng SF, Chen GR, Lin YX, Kang DZ.
422 2018. High-Density Lipoprotein Is Associated with Progression of Intracranial Aneurysms. *World*
423 *neurosurgery*. 120:e234-e240. DOI: 10.1016/j.wneu.2018.08.037
- 424 Bowden J, Davey Smith G, Burgess S. 2015. Mendelian randomization with invalid instruments: effect
425 estimation and bias detection through Egger regression. *International journal of epidemiology*.
426 442:512-525. DOI: 10.1093/ije/dyv080
- 427 Bowden J, Davey Smith G, Haycock PC, Burgess S. 2016. Consistent Estimation in Mendelian
428 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genetic*
429 *epidemiology*. 404:304-314. DOI: 10.1002/gepi.21965
- 430 Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, Reeve MP, Laivuori H,
431 Aavikko M, Kaunisto MA, Loukola A, Lahtela E, Mattsson H, Laiho P, Della Briotta Parolo P, Lehisto
432 AA, Kanai M, Mars N, Rämö J, Kiiskinen T, Heyne HO, Veerapen K, Rüeger S, Lemmelä S, Zhou W,
433 Ruotsalainen S, Pärn K, Hiekkalinna T, Koskelainen S, Paajanen T, Llorens V, Gracia-Tabuenca J,
434 Siirtola H, Reis K, Elnahas AG, Sun B, Foley CN, Aalto-Setälä K, Alasoo K, Arvas M, Auro K, Biswas
435 S, Bizaki-Vallaskangas A, Carpen O, Chen CY, Dada OA, Ding Z, Ehm MG, Eklund K, Färkkilä M,
436 Finucane H, Ganna A, Ghazal A, Graham RR, Green EM, Hakanen A, Hautalahti M, Hedman Å K,
437 Hiltunen M, Hinttala R, Hovatta I, Hu X, Huertas-Vazquez A, Huilaja L, Hunkapiller J, Jacob H,
438 Jensen JN, Joensuu H, John S, Julkunen V, Jung M, Junttila J, Kaarniranta K, Kähönen M, Kajanne R,
439 Kallio L, Kälviäinen R, Kaprio J, Kerimov N, Kettunen J, Kilpeläinen E, Kilpi T, Klinger K, Kosma
440 VM, Kuopio T, Kurra V, Laisk T, Laukkanen J, Lawless N, Liu A, Longgerich S, Mägi R, Mäkelä J,
441 Mäkitie A, Malarstig A, Mannermaa A, Maranville J, Matakidou A, Meretoja T, Mozaffari SV, Niemi
442 MEK, Niemi M, Niiranen T, CJ OD, Obeidat ME, Okafo G, Ollila HM, Palomäki A, Palotie T,
443 Partanen J, Paul DS, Pelkonen M, Pendergrass RK, Petrovski S, Pitkäranta A, Platt A, Pulford D,
444 Punkka E, Pussinen P, Raghavan N, Rahimov F, Rajpal D, Renaud NA, Riley-Gillis B, Rodosthenous
445 R, Saarentaus E, Salminen A, Salminen E, Salomaa V, Schleutker J, Serpi R, Shen HY, Siegel R,
446 Silander K, Siltanen S, Soini S, Soininen H, Sul JH, Tachmazidou I, Tasanen K, Tienari P,
447 Toppila-Salmi S, Tukiainen T, Tuomi T, Turunen JA, Ulirsch JC, Vaura F, Virolainen P, Waring J,
448 Waterworth D, Yang R, Nelis M, Reigo A, Metspalu A, Milani L, Esko T, Fox C, Havulinna AS, Perola
449 M, Ripatti S, Jalanko A, Laitinen T, Mäkelä TP, Plenge R, McCarthy M, Runz H, Daly MJ, Palotie A.
450 2023. FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature*.
451 6137944:508-518. DOI: 10.1038/s41586-022-05473-8
- 452 Pierce BL, Ahsan H, Vanderweele TJ. 2011. Power and instrument strength requirements for Mendelian
453 randomization studies using multiple genetic variants. *International journal of epidemiology*.
454 403:740-752. DOI: 10.1093/ije/dyq151
- 455 Park JH, Wacholder S, Gail MH, Peters U, Jacobs KB, Chanock SJ, Chatterjee N. 2010. Estimation of
456 effect size distribution from genome-wide association studies and implications for future discoveries.
457 *Nature genetics*. 427:570-575. DOI: 10.1038/ng.610
- 458 Ge P, Liu C, Chan L, Pang Y, Li H, Zhang Q, Ye X, Wang J, Wang R, Zhang Y, Wang W, Zhang D,
459 Zhao J. 2022. High-Dimensional Immune Profiling by Mass Cytometry Revealed the Circulating
460 Immune Cell Landscape in Patients With Intracranial Aneurysm. *Frontiers in immunology*. 13:922000.
461 DOI: 10.3389/fimmu.2022.922000

- 462 Nakatomi H, Segawa H, Kurata A, Shiokawa Y, Nagata K, Kamiyama H, Ueki K, Kirino T. 2000.
463 Clinicopathological study of intracranial fusiform and dolichoectatic aneurysms : insight on the
464 mechanism of growth. *Stroke*. 314:896-900. DOI: 10.1161/01.str.31.4.896
- 465 Meng H, Tutino VM, Xiang J, Siddiqui A. 2014. High WSS or low WSS? Complex interactions of
466 hemodynamics with intracranial aneurysm initiation, growth, and rupture: toward a unifying hypothesis.
467 *AJNR American journal of neuroradiology*. 357:1254-1262. DOI: 10.3174/ajnr.A3558
- 468 Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, Nyska A, Wachsmen JT,
469 Ames BN, Basu S, Brot N, Fitzgerald GA, Floyd RA, George M, Heinecke JW, Hatch GE, Hensley K,
470 Lawson JA, Marnett LJ, Morrow JD, Murray DM, Plastaras J, Roberts LJ, 2nd, Rokach J, Shigenaga
471 MK, Sohal RS, Sun J, Tice RR, Van Thiel DH, Wellner D, Walter PB, Tomer KB, Mason RP, Barrett JC.
472 2005. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA
473 markers of CCl₄ poisoning? *Free radical biology & medicine*. 386:698-710. DOI:
474 10.1016/j.freeradbiomed.2004.09.017
- 475 Saraswathi V, Gao L, Morrow JD, Chait A, Niswender KD, Hasty AH. 2007. Fish oil increases
476 cholesterol storage in white adipose tissue with concomitant decreases in inflammation, hepatic
477 steatosis, and atherosclerosis in mice. *The Journal of nutrition*. 137:1776-1782. DOI:
478 10.1093/jn/137.7.1776
- 479 Zúñiga J, Venegas F, Villarreal M, Núñez D, Chandía M, Valenzuela R, Tapia G, Varela P, Videla LA,
480 Fernández V. 2010. Protection against in vivo liver ischemia-reperfusion injury by n-3 long-chain
481 polyunsaturated fatty acids in the rat. *Free radical research*. 448:854-863. DOI:
482 10.3109/10715762.2010.485995
- 483 Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ. 2003. Effect of eicosapentaenoic
484 acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive
485 type 2 diabetic subjects. *Free radical biology & medicine*. 357:772-781. DOI:
486 10.1016/s0891-5849(03)00407-6
- 487 Barden AE, Burke V, Mas E, Beilin LJ, Puddey IB, Watts GF, Irish AB, Mori TA. 2015. n-3 fatty acids
488 reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney
489 disease. *Journal of hypertension*. 339:1947-1953. DOI: 10.1097/hjh.0000000000000621
- 490 Nakagawa I, Yokoyama S, Omoto K, Takeshima Y, Matsuda R, Nishimura F, Yamada S, Yokota H,
491 Motoyama Y, Park YS, Nakase H. 2017. ω-3 Fatty Acids Ethyl Esters Suppress Cerebral Vasospasm
492 and Improve Clinical Outcome Following Aneurysmal Subarachnoid Hemorrhage. *World neurosurgery*.
493 99:457-464. DOI: 10.1016/j.wneu.2016.12.018
- 494 Saito G, Zapata R, Rivera R, Zambrano H, Rojas D, Acevedo H, Ravera F, Mosquera J, Vásquez JE,
495 Mura J. 2017. Long-chain omega-3 fatty acids in aneurysmal subarachnoid hemorrhage: A randomized
496 pilot trial of pharmaconutrition. *Surgical neurology international*. 8:304. DOI: 10.4103/sni.sni_266_17
- 497 Gewirtz RJ, Dhillon HS, Goes SE, DeAtley SM, Scheff SW. 1999. Lactate and free fatty acids after
498 subarachnoid hemorrhage. *Brain research*. 8401-2:84-91. DOI: 10.1016/s0006-8993(99)01752-7
- 499 Ikedo T, Minami M, Kataoka H, Hayashi K, Nagata M, Fujikawa R, Yamazaki F, Setou M, Yokode M,
500 Miyamoto S. 2018. Imaging mass spectroscopy delineates the thinned and thickened walls of
501 intracranial aneurysms. *Biochemical and biophysical research communications*. 4951:332-338. DOI:
502 10.1016/j.bbrc.2017.10.133
- 503 Simopoulos AP. 2010. Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their
504 role in the determination of nutritional requirements and chronic disease risk. *Experimental biology
505 and medicine (Maywood, NJ)*. 2357:785-795. DOI: 10.1258/ebm.2010.009298

506 Plunde O, Larsson SC, Artiach G, Thanassoulis G, Carracedo M, Franco-Cereceda A, Eriksson P, Bäck
507 M. 2020. FADS1 (Fatty Acid Desaturase 1) Genotype Associates With Aortic Valve FADS mRNA
508 Expression, Fatty Acid Content and Calcification. *Circulation Genomic and precision medicine*.
509 133:e002710. DOI: 10.1161/circgen.119.002710

510

511

512 **Figure legends**

513 Figure 1. Flowchart showing Mendelian randomization.

514 MR, Mendelian randomization; MR-PRESSO, Mendelian randomization pleiotropy residual sum and
515 outlier; SNPs, single-nucleotide polymorphisms; MVMR, multivariable Mendelian randomization;
516 IVW: inverse variance weighting; PUFA: polyunsaturated fatty acids; COLOC: colocalization.

517

518 Figure 2. Mendelian randomization analysis of the association between PUFA and IA.

519 PUFA: polyunsaturated fatty acids; IA: intracranial aneurysm; OR: odds ratio; CI: confidence interval;
520 MR, Mendelian randomization; IVW: inverse variance weighting; DHA: docosahexaenoic acid.

521

522 Figure 3. Mendelian randomization analysis of the association between PUFA and aSAH.

523 PUFA: polyunsaturated fatty acids; aSAH: aneurysmal subarachnoid hemorrhage; OR: odds ratio; CI:
524 confidence interval; MR, Mendelian randomization; IVW, inverse variance weighting; DHA:
525 docosahexaenoic acid.

526

527 Figure 4. Mendelian randomization analysis of the association between PUFA and uIA.

528 PUFA: polyunsaturated fatty acids; uIA: unruptured intracranial aneurysm; OR: odds ratio; CI:
529 confidence interval; MR, Mendelian randomization; IVW, inverse variance weighting; DHA:
530 docosahexaenoic acid.

531

532 Figure 5. Multivariable Mendelian randomization analysis of the association between PUFA and IA.

533 IA: intracranial aneurysm; DHA: docosahexaenoic acid; LDL: low density lipoprotein; HDL: high
534 density lipoprotein.

535

536 Figure 6. Multivariable Mendelian randomization analysis of the association between PUFA and
537 aSAH.

538 aSAH: aneurysmal subarachnoid hemorrhage; DHA: docosahexaenoic acid; LDL: low density
539 lipoprotein; HDL: high density lipoprotein.

540

541 Figure 7. Multivariable Mendelian randomization analysis of the association between PUFA and uIA.


542 uIA: unruptured intracranial aneurysm; DHA: docosahexaenoic acid; LDL: low density lipoprotein;
543 HDL: high density lipoprotein.

544

545 Figure 8. The sensitivity analysis of the association between PUFA and CA after remove FADS2 locus.


546 IA: intracranial aneurysm; aSAH: aneurysmal subarachnoid hemorrhage; uIA: unruptured intracranial
547 aneurysm; DHA: docosahexaenoic acid; IVW: inverse variance weighting

548




Outcome	Exposure	Method	OR(95%CI)	p-value
IA	Omega-3	IVW	0.80(0.69 to 0.91)	1.01E-03
	DHA		0.75(0.63 to 0.87)	3.12E-04
	Omega-3-pct		0.80(0.71 to 0.90)	2.34E-04
	Omega-6 by Omega-3		1.27(1.12 to 1.44)	1.53E-04
	Omega-6		0.78(0.57 to 1.06)	1.13E-01

p<0.0033 was considered statistically significant




Outcome	Exposure	Method	OR(95%CI)		p-value
aSAH	Omega-3	IVW	0.71(0.61 to 0.84)		3.73E-05
	DHA		0.67(0.55 to 0.80)		2.32E-05
	Omega-3-pct		0.76(0.66 to 0.87)		1.16E-04
	Omega-6 by Omega-3		1.35(1.17 to 1.56)		5.78E-05
	Omega-6		0.82(0.62 to 1.08)		1.53E-01


p<0.0033 was considered statistically significant




Outcome	Exposure	Method	OR(95%CI)	p-value
uIA	Omega-3	IVW	0.91(0.76 to 1.08)	2.68E-01
	DHA		0.93(0.76 to 1.14)	4.79E-01
	Omega-3-pct		0.97(0.82 to 1.13)	6.65E-01
	Omega-6 by Omega-3		1.01(0.90 to 1.25)	4.82E-01
	Omega-6		0.87(0.62 to 1.24)	4.43E-01


p < 0.0033 was considered statistically significant






* p<0.0033 was considered statistically significant







Outcome	Exposure	Method	P	OR(95%CI)
IA	Omega-3	IVW	0.225	0.79(0.52 to 1.18)
	DHA		0.030	0.56(0.34 to 0.94)
	Omega-3-pct		0.019	0.54(0.33 to 0.91)
	Omega-6 by Omega-3		0.008	1.74(1.15 to 2.62)
aSAH	Omega-3	IVW	0.060	0.56(0.30 to 1.03)
	DHA		0.089	0.58(0.31 to 1.09)
	Omega-3-pct		0.011	0.18(0.05 to 0.68)
	Omega-6 by Omega-3		0.005	2.84(0.99 to 8.16)
uIA	Omega-3	IVW	0.063	0.67(0.44 to 1.02)
	DHA		0.015	0.50(0.29 to 0.88)
	Omega-3-pct		0.111	0.66(0.40 to 1.10)
	Omega-6 by Omega-3		0.019	1.87(1.11 to 3.16)

p<0.0033 was considered statistically significant

